睿智医药收盘上涨19.98%，最新市净率4.75，总市值58.01亿元

Group 1 - The core viewpoint of the news is that Ruizhi Pharmaceutical's stock has seen a significant increase, closing at 11.65 yuan, up 19.98%, with a market capitalization of 5.801 billion yuan, marking a new low in the price-to-book ratio at 4.75 over the past 600 days [1] - On June 9, the net inflow of main funds into Ruizhi Pharmaceutical was 245.4361 million yuan, although the overall trend over the past five days showed a net outflow of 121.2023 million yuan [1] - The company specializes in providing drug discovery, development, and production services to global pharmaceutical enterprises, biotechnology companies, and research institutions, with main products including chemical business, pharmacodynamics, and macromolecule business [1] Group 2 - The latest quarterly report for Q1 2025 shows that Ruizhi Pharmaceutical achieved an operating income of 261 million yuan, representing a year-on-year increase of 11.37%, and a net profit of 6.6421 million yuan, which is a year-on-year increase of 126.09%, with a gross profit margin of 27.44% [1] - The company's price-to-earnings (PE) ratio (TTM) is -29.85, and the static PE is -25.62, with a market capitalization of 5.801 billion yuan, compared to the industry average PE of 41.42 and industry median PE of 44.32 [2] - The company is positioned within an industry where the average market capitalization is 160.55 billion yuan, indicating a relatively smaller size compared to its peers [2]